Decreased natural killer (NK) activity in patients with myeloproliferative disorders
- PMID: 2788028
- DOI: 10.1002/1097-0142(19890901)64:5<1038::aid-cncr2820640513>3.0.co;2-w
Decreased natural killer (NK) activity in patients with myeloproliferative disorders
Abstract
Natural killer (NK) cell number and activity were measured in 26 patients with myeloproliferative disorders and the results were compared with 16 age-matched control patients. The percent of Leu-11b-positive cells was 11% +/- 3% in the patients, compared with 12% +/- 4% in the control patients. Ten of 26 patients, however, had NK activity lower than all of the control values at three different effector to target cell ratios (E:T) (P less than 0.005). The values of those patients with low unstimulated NK activity remained low despite stimulation with interleukin-2 (IL-2) or alpha-interferon (alpha-IFN), whereas the values of those patients with normal unstimulated activity responded to IL-2 and alpha-IFN like the control patients. Three of the ten patients with low NK activity had a history of malignant neoplasms. None of the 16 patients with normal NK activity had a history of malignant neoplasms (P less than 0.05). We conclude that patients with myeloproliferative disorders frequently have low endogenous NK cell activity in vitro. The dysfunction of the NK system appears to be intrinsic because the relative number of NK cells was similar to control values and the response to stimulation with IL-2 and alpha-IFN was suboptimal. There may be a relationship between low NK activity and the development of malignant disease in such patients.
Similar articles
-
Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.Nat Immun. 1993 May-Jun;12(3):136-51. Nat Immun. 1993. PMID: 8329837
-
Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.Eur J Haematol. 2015 Mar;94(3):227-34. doi: 10.1111/ejh.12420. Epub 2014 Sep 24. Eur J Haematol. 2015. PMID: 25082025
-
[The role of natural killer cell activity in the pathogenesis of chronic myeloproliferative diseases].Lik Sprava. 1993 Jul;(8):70-3. Lik Sprava. 1993. PMID: 8079482 Russian.
-
Immunologic dysfunction in the myeloproliferative disorders.Cancer. 1978 Jul;42(1):149-58. doi: 10.1002/1097-0142(197807)42:1<149::aid-cncr2820420125>3.0.co;2-i. Cancer. 1978. PMID: 276412
-
Natural killer activity: early days, advances, and seminal observations.Crit Rev Oncog. 2014;19(1-2):1-13. doi: 10.1615/critrevoncog.2014011125. Crit Rev Oncog. 2014. PMID: 24941370 Free PMC article. Review.
Cited by
-
Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms.Front Immunol. 2022 Sep 23;13:768592. doi: 10.3389/fimmu.2022.768592. eCollection 2022. Front Immunol. 2022. PMID: 36211444 Free PMC article.
-
Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.Biomolecules. 2022 May 27;12(6):754. doi: 10.3390/biom12060754. Biomolecules. 2022. PMID: 35740879 Free PMC article. Review.
-
PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review.Int J Mol Sci. 2022 May 23;23(10):5837. doi: 10.3390/ijms23105837. Int J Mol Sci. 2022. PMID: 35628647 Free PMC article. Review.
-
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.Cancers (Basel). 2021 Sep 23;13(19):4750. doi: 10.3390/cancers13194750. Cancers (Basel). 2021. PMID: 34638236 Free PMC article. Review.
-
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.Oncoimmunology. 2020 Jun 23;9(1):1782575. doi: 10.1080/2162402X.2020.1782575. Oncoimmunology. 2020. PMID: 32923146 Free PMC article.